Key result
GLP-1 improves endothelial function in hypertensive mice via CREB-driven lncRNA transcription and Akt/eNOS activation.
Why the study?
The regulatory mechanism of GLP-1 on lncRNA 155383 and the role of this lncRNA in endothelial homeostasis remained unclear.
Does GLP-1 signaling improve vascular endothelial dysfunction in hypertensive mice via lncRNA 155383?
Does GLP-1 signaling improve vascular endothelial dysfunction in hypertensive mice via lncRNA 155383?
GLP-1 signaling improves endothelial function in hypertension via a CREB-driven lncRNA 155383/miR-214-3p/PMCA4/Akt/eNOS pathway, highlighting a novel molecular mechanism for vascular protection.
Answers are grounded in this paper and cite their sources.
May link lncRNA 155383 to eNOS effects in hypertensive models; leaves open human relevance.
Background and Purpose Agents targeting the glucagon‐like peptide‐1 (GLP‐1) signalling pathway, including dipeptidyl peptidase 4 (DPP‐4) inhibitors and GLP‐1 receptor agonists, exert biological effects through regulating long noncoding RNAs (lncRNAs). We previously identified ENSMUST00000155383 (lncRNA 155383) as a potential contributor to DPP‐4 inhibitor MK‐626‐induced endothelial nitric oxide synthase (eNOS) phosphorylation in endothelial cells from hypertensive mice. However, the regulatory mechanism of GLP‐1 on lncRNA 155383 and role of this lncRNA in endothelial homeostasis remain unclear. Experimental Approach Mice were treated with shRNA adenovirus for lncRNA 155383 knockdown. Vascular function was evaluated by wire myograph. Molecular mechanisms were investigated using ChIP‐qPCR, subcellular fractionation analysis, fluorescence in situ hybridization and dual‐luciferase reporter assays. Key Results LncRNA 155383 knockdown abolished the vaso‐protective effects of MK‐626 in hypertensive mice and induced endothelial dysfunction in normotensive controls. MK‐626 activated cAMP‐response element‐binding protein (CREB), which bound to the lncRNA 155383's promoter, thereby driving its transcription. LncRNA 155383 was mainly localized in the cytoplasm, where it functioned as a competing endogenous RNA, sponging miR‐214‐3p to preserve plasma membrane Ca 2+ ATPase 4 (PMCA4) expression. Up‐regulated PMCA4 subsequently activated the Akt/eNOS pathway, restoring endothelial function. Similar ameliorative effect of a GLP‐1 receptor agonist exendin‐4 on angiotensin II‐induced endothelial injury in vitro was observed. Conclusions and Implications GLP‐1 might improve endothelial function via CREB‐driven lncRNA 155383 transcription, which sponges miR‐214‐3p to up‐regulate PMCA4 and activate downstream Akt/eNOS signalling. These findings uncover a novel molecular basis of GLP‐1‐mediated vascular protection and implicate lncRNA 155383 as a possible therapeutic target in hypertension.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Hypertension. GLP-1 signalling pathway agents (MK-626, exendin-4) vs. Control was evaluated on Vascular endothelial function. GLP-1 improves endothelial function in hypertensive mice via CREB-driven lncRNA 155383 transcription, which sponges miR-214-3p to up-regulate PMCA4 and activate Akt/eNOS signalling.
Synapse has enriched 10 related papers. Consider them for comparative context: